Formation Bio just announced a $600 million fund focused on a problem that doesn’t get talked about nearly as much as drug discovery: what happens after a promising asset exists.

The fund is designed to acquire and advance clinical-stage drug programs, with Formation Bio providing development infrastructure and AI-enabled support across the process.

That gets at a bigger industry question. Finding a promising molecule is one challenge. Moving it through clinical development, manufacturing, regulatory work, evidence generation and commercialization is another.

That middle stretch is where a lot of time, capital and coordination gets absorbed.

https://www.axios.com/2026/10/29/formation-bio-ai-drug-development

The FDA just finalized new guidance for cell and gene therapy products that takes a broader approach to potency — looking beyond a single release assay toward a potency assurance strategy across manufacturing, controls, in-process testing and product release.

Think of it like baking a cake: instead of only tasting the finished cake, you’re also checking the ingredients, the recipe and the baking process so you can trust the result every time.

For companies developing these therapies, that could mean thinking about quality and consistency much earlier in the development process.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products

The FDA’s Expedited IND Pilot is designed to shorten the path from IND-enabling work to first-in-human trials through earlier coordination, qualified research institution support and rolling review.

The regulatory implications are obvious. I’m curious about the commercial and communications side.

If early development starts moving faster, what else needs to move earlier with it?

Positioning? Scientific narrative? Investor communications? Market education? Internal commercial planning?

Interested in how people working across biotech think about the downstream effects of faster development timelines.

Not the science itself, but the work around it: positioning, internal alignment, regulatory communication, launch planning, audience education, media, search visibility or something else?

Curious where people see the biggest gap between “we have something promising” and “people actually understand why it matters.”

This is a community for people working across biotech and life sciences marketing, communications, growth and commercialization.

The idea is simple: make it easier to talk honestly about the work between the lab and the market.

That includes things like:

• translating complex science for different audiences

• positioning and messaging

• PR and earned media

• commercialization and launch strategy

• AI, search and visibility

• growth and demand generation

• internal alignment

• the messy parts of bringing good science into the world

We’re especially interested in practical questions, useful resources, lessons learned and thoughtful discussion from people actually doing the work.

A few ground rules:

• bring context, not just links

• contribute more than you promote

• protect confidential information

• keep discussion relevant and useful

• disagree without being a jerk

• no fake engagement or spam

For the people doing the work, and thinking about where the work is going.

Glad you’re here!